NEXT Life Sciences Launches Clinical Trials for Plan A™ Male Contraceptive

A small vial with "plan a" written on the front

NEXT Life Sciences

News POSTED Mar 24, 2025 By CTI Exchange Staff

NEXT Life Sciences has announced the launch of clinical trials for Plan A™, a long-lasting, reversible, and hormone-free male contraceptive. The trials, set to begin in Australia on March 24, 2025, mark a significant step forward for Plan A™, a product that utilizes a proprietary hydrogel that filters out sperm for up to 10 years, offering men a reliable and convenient contraceptive option. The clinical trials are supported by the Male Contraceptive Initiative (MCI), which has provided additional funding to advance the development of Plan A™.

In a recent episode of the Healthcare Strategies podcast, Dr. Walley, CEO of NEXT Life Sciences, discussed the science behind Plan A™ and its potential to transform reproductive health choices for men. Unlike traditional female contraceptives, Plan A™ does not rely on hormonal manipulation. Instead, it employs Vasalgel, a high molecular weight polymer that forms a semi-solid barrier in the vas deferens, blocking sperm while allowing the passage of seminal fluids.